Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

3DMed and Alphamab Start Joint Development of China PD-L1 Cancer Drug

publication date: Mar 4, 2016
3DMed, a Shanghai biotech, and Suzhou's Alphamab have decided to join forces to develop KN035, a PD-L1 immuno-oncology drug discovered by Alphamab. Unlike most PD-L1 mAbs, KN035 is an injected product that the companies hope will be more effective and cause fewer side effects than the competition. 3DMed and Alphamab will develop KN035 equally. They expect to file for China clinical trial approval in Q2 and begin the trials before the end of the year, with US trials following later. Further details of the agreement were not disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital